Breast cancer risk in young women in the national breast screening programme: Implications for applying NICE guidelines for additional screening and chemoprevention

Cancer Prevention Research

Volumn 7, Issue 10, 2014, Pages 993-1001

  Evans, D Gareth ^a,b,c   Brentnall, Adam R ^d   Harvie, Michelle ^a   Dawe, Sarah ^a   Sergeant, Jamie C ^a,b,e   Stavrinos, Paula ^a   Astley, Susan ^a,e   Wilson, Mary ^a   Ainsworth, John ^e   Cuzick, Jack ^d   Buchan, Iain ^e   Donnelly, Louise S ^a   Howell, Anthony ^a,c  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; TAMOXIFEN;

ADULT; ALCOHOL CONSUMPTION; ALGORITHM; ARTICLE; ATYPICAL DUCTAL HYPERPLASIA; BODY MASS; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOMA; BREAST DENSITY; BREAST DISEASE; BREAST FEEDING; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CHEMOPROPHYLAXIS; CONTROLLED STUDY; ESTROGEN BLOOD LEVEL; FAMILY HISTORY; FEMALE; GENETIC SCREENING; GROUPS BY AGE; HEALTH CARE ORGANIZATION; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; LIVE BIRTH; MAJOR CLINICAL STUDY; MALE BREAST CANCER; MAMMOGRAPHY; MATERNAL AGE; MENARCHE; MENOPAUSE; MIDDLE AGED; NATIONAL INSTITUTE OF HEALTH CARE EXCELLENCE; ONCOGENE; ORAL CONTRACEPTION; OVARY CANCER; PARITY; PRACTICE GUIDELINE; PREDICTION; PREMENOPAUSE; PRIMARY MEDICAL CARE; QUESTIONNAIRE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; THIRD DEGREE RELATIVE; BREAST NEOPLASMS; EARLY DIAGNOSIS; MASS SCREENING; RISK FACTOR; STANDARDS; UNITED KINGDOM;

ADULT; ALGORITHMS; BREAST NEOPLASMS; CHEMOPREVENTION; EARLY DETECTION OF CANCER; FEMALE; GREAT BRITAIN; HUMANS; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; TAMOXIFEN;

EID: 84907558200     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0037     Document Type: Article

References (40)

1. CR-UK, CancerStats Incidence-UK. Cancer Research UK 2011. Accessed Jan 2014. Available from: www.cancerresearchuk.org.
2. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-6.
3. Tryggvadottir L, Sigvaldason H, Olafsdottir GH, Jonasson JG, Jonsson T, Tulinius H, et al. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000. J Natl Cancer Inst 2006;98:116-22.
4. Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in the service setting: higher risk in recent birth cohorts. BMC Cancer 2008;8:155.
5. Marmot M. Independent UK Panel on Breast Cancer Screening, Altman G, Cameron DA, Dewar JA, Thompson SG, Wilcox M. Independent UK panel on breast cancer screening replies to Michael Baum. BMJ 2013;346:f873. doi: 10.1136/bmj.f3829.
6. National Collaborating Centre for Cancer. Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. Update of clinical guideline 14 and 41. Clinical guideline 164. London: NCCC, 2013. Available from: http://guidance.nice.org.uk/CG164 (Accessed 23 July 2013).
7. Evans DG, Graham J, O'Connell S, Arnold S, Fitzsimmons D. Familial breast cancer: summary of updated NICE guidance. BMJ 2013;346: f3829. doi: 10.1136/bmj.f3829.
8. Pharoah PD, Sewell B, Fitzsimmons D, Bennett HS, Pashayan N. Cost effectiveness of the NHS Breast Screening Programme: life table model. BMJ 2013;346:f2618.
9. Schousboe JT, Kerlikowske K, Loh A, Cummings SR. Personalizing mammography by breast density and other risk factors for breast cancer: Analysis of health benefits and cost-effectiveness. Ann Intern Med 2011;155:10-20.
10. de Bock GH, Vermeulen KM, Jansen L, Oosterwijk JC, Siesling S, Dorrius MD, et al. Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness. Br J Cancer 2013;108:1579-86.
11. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, et al. Long-term results of tamoxifen prophylaxis for breast cancer 96- month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007;99:272-82.
12. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, et al. Preventive therapy for breast cancer: A consensus statement. Lancet Oncol 2011;12:496-503.
13. Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, Decensi A, et al. Selective oestrogen receptor modulators in prevention of breast cancer: An updated meta-analysis of individual participant data. Lancet 2013;381:1827-34.
14. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res 2010;3:696-706.
15. Evans DG, Warwick J, Astley SM, Stavrinos P, Sahin S, Ingham SL, et al. Assessing individual breast cancer risk within the UK National Health Service Breast Screening Programme: A new paradigm for cancer prevention. Cancer Prev Res 2012;5:943-51. Available from: (http://www.uhsm.nhs.uk/research/Documents/PROCAS%20Questionnaire.pdf).
16. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23:1111-30.
17. Pashayan N, Duffy SW, Chowdhury S, Dent T, Burton H, Neal DE, et al. Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer 2011;104:1656-63.
18. Weisstock CR, Rajapakshe R, Bitgood C, McAvoy S, Gordon PB, Coldman AJ, et al. Assessing the breast cancer risk distribution for women undergoing screening in British Columbia. Cancer Prev Res 2013;6:1084-92.
19. Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 2003;40:807-14.
20. Leggatt V, Mackay J, Yates JR. Evaluation of questionnaire on cancer family history in identifying patients at increased genetic risk in general practice. BMJ 1999;319:757-8.
21. Johnson N, Lancaster T, Fuller A, Hodgson SV. The prevalence of a family history of cancer in general practice. Fam Pract 1995;12:287-9.
22. Eccles DM, Evans DGR, Mackay J. Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. J Med Genet 2000:37:203-9.
23. van Asperen CJ, Tollenaar RA, Krol-Warmerdam EM, Blom J, Hoogendoorn WE, Seynaeve CM, et al. Possible consequences of applying guidelines to healthy women with a family history of breast cancer. Eur J Hum Genet 2003;11:633-67.
24. Quante AS, Whittemore AS, Shriver T, Strauch K, Terry MB Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res 2012;14:R144.
25. The Canadian Task Force on Preventive Health Care. Recommendations on screening for breast cancer in average-risk women aged 40-74 years. CMAJ 2011;183:1991-2001.
26. US Preventive task forces recommendations on breast cancer screening 2009. Available from: http://www.uspreventiveservicestaskforce.org/uspstf09/breastcancer/brcanrs.htm.
27. Amir E, Freedman OC, Seruga B, Evans DG. Assessing women at high risk of breast cancer: A review of risk assessment models. J Natl Cancer Inst 2010;102:680-91.
28. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individulized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86. Available from: http://bcra.nci.nih.gov/brc/q1.htm.
29. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91:1541-48.
30. Euhus DM, Leitch AM, Huth JF, Peters GN. Limitations of the Gail model in the specialized breast cancer risk assessment clinic. Breast 2002;8:23-7.
31. Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat 1993;28:115-120.
32. Parmigiani G, Berry DA, Aquilar O. Determining carrier probabilities for breast cancer susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145-148.
33. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008;98:2015.
34. Boyd NF, et al.Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 2002;347:886-94.
35. Pankow JS, et al.Genetic analysis of mammographic breast density in adult women: evidence of a gene effect. J Natl Cancer Inst 1997;89: 549-56.
36. Santen R, Boyd N, Chlebowski RT, Cummings S, Cuzick J, Dowsett M, et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocrine-related cancer 2007;14:169-187.
37. Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 2006;98:1204-14.
38. Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C, et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. JNCI 2006;98: 1215-26.
39. Available from: http://www.bmj.com/content/346/bmj.f4116.
40. Li J, Foo JN, Schoof N, Varghese JS, Fernandez-Navarro P, Gierach GL, et al. Large-scale genotyping identifies a new locus at 22q13.2 associated with female breast size. J Med Genet 2013;50:666-73.